Clinical evaluation of a new Ultra-Rapid Antibiotic Susceptibility Test in Blood Stream Infections
|Coordinator||Astrego Diagnostics AB|
|Funding from Vinnova||SEK 1 671 000|
|Project duration||December 2018 - December 2019|
|Venture||Medtech4Health - medicintekniska samverkansprojekt|
|Call||Medtech4Health: Medicintekniska samverkansprojekt - 2018|
Purpose and goal
The aim of the project is to evaluate the possibilities and limitations for the use of the Astrego® technology with clinical samples from patients with blood stream infections in central lab settings. The project goal is to develop a user requirement specification for (at least) one product, based on the Astrego’s unique technology, with potential to have a big impact on improving the treatment of blood stream infections and sepsis patients.
Expected results and effects
WHO recently published a Global action plan on antimicrobial resistance, which emphasize the need for rapid, reliable and cost-effective diagnostics to enable improved antibiotic stewardship. In parallel, improved sepsis treatment was appointed a global health priority by WHO. Astrego Diagnostics have a unique technology with a potential to fulfil both these global needs, and at the same time make Astrego a major player on a large and continuously growing global market.
Planned approach and implementation
The project is a collaboration between Astrego Diagnostics and Dept. of Laboratory Medicine at Karolinska Institute. Astrego will provide prototype instruments and disposable cartridges to researchers at Karolinska that have access to a large number of patient samples. The collaboration will enable Astrego to evaluate the suitability of the unique technology for blood stream infections, but also to collect usability feed-back and to document user-requirements for a future product in this field.